Various presentations of gestational trophoblastic disease and its outcomes in a tertiary hospital
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20250176Keywords:
Beta-hCG, Gestational trophoblastic disease, Gestational trophoblastic neoplasia, Molar pregnancyAbstract
Background: Gestational trophoblastic disease encompasses a heterogeneous group of lesions arising from abnormal placental trophoblast proliferation. While molar pregnancy is the most common form, gestational trophoblastic neoplasia, though rare and often curable even with widespread dissemination, can follow any gestational event, including abortion, ectopic pregnancy, or term pregnancy. The aim of the study was to evaluate the various presentations and outcomes of gestational trophoblastic disease (GTD) in a tertiary hospital setting.
Methods: This retrospective study, conducted in the department of gynecological oncology at BSMMU from June 2023 to July 2024, included 173 patients with GTD. Diagnoses were confirmed using ultrasonography, serum beta-hCG, and histopathology. Data were retrospectively collected from medical records, documenting key demographic and clinical information. Ethical approval and informed consent were obtained. Data analysis was performed using SPSS version 22.
Results: Most participants were between 25-34 years (91.91%). The majority of GTD cases (54.91%) occurred in the 20-25 years age group, with bleeding per vagina being the most common clinical presentation (91.91%). Histopathology classified 72.83% of cases as complete moles. Treatment resulted in complete resolution for 85.55% of cases. Pre-evacuation beta hCG levels were above 100,000 IU/l in 72.83% of cases.
Conclusions: This study highlights the diverse presentations and favorable outcomes of gestational trophoblastic disease (GTD) in a tertiary hospital, emphasizing the importance of tailored management and monitoring strategies.
Metrics
References
Tamang T, Tshomo U. Incidence and clinicopathological profile of gestational trophoblastic disease in tertiary care centre. Bhutan Health J. 2018;4(2):25-9. DOI: https://doi.org/10.47811/bhj.64
Kumari A, Chauhan N. Gestational trophoblastic diseases: an observational study at a tertiary care teaching hospital in Jharkhand, India. Int J Reprod Contracept Obstet Gynecol. 2020;9(8):3139. DOI: https://doi.org/10.18203/2320-1770.ijrcog20203044
Antaratani RC, Shruthi M. Study of gestational trophoblastic diseases at a tertiary care hospital in India. Int J Reprod Contracept Obstet Gynecol. 2018;7(4):1622-8. DOI: https://doi.org/10.18203/2320-1770.ijrcog20181367
Mulik J, Choudhary A. Clinical study of gestational trophoblastic disease in a tertiary care hospital. Int J Reprod Contracept Obstet Gynecol. 2020;9(7):2964-9. DOI: https://doi.org/10.18203/2320-1770.ijrcog20202741
Agrawal N, Sagtani RA, Budhathoki SS, Pokharel HP. Clinico-epidemiological profile of molar pregnancies in a tertiary care centre of eastern Nepal: a retrospective review of medical records. Gynecol Oncol Res Pract. 2015;2:9. DOI: https://doi.org/10.1186/s40661-015-0017-y
Anyanwu M, Bah K. A cross sectional descriptive study on hydatidiform mole at Gambian tertiary hospital. Women’s Health. 2020;9(1):1-5. DOI: https://doi.org/10.15406/mojwh.2020.09.00260
Berek JS, Hacker NF. Berek and Hacker’s Gynecologic Oncology, 7th edn. Philadelphia: Lippincott Williams and Wilkins; 2021.
Mulisya O, Roberts DJ, Sengupta ES, Agaba E, Laffita D, Tobias T, et al. Prevalence and factors associated with hydatidiform mole among patients undergoing uterine evacuation at mbarara regional referral hospital. Obstet Gynecol Int. 2018;2018(1):9561413. DOI: https://doi.org/10.1155/2018/9561413
Patel O, Pradhan S, Dora SK, Mohanty S. Clinicopathological study of gestational trophoblastic diseases. J Pharm Negat Results. 2022:8964-72.
Jagtap SV, Aher V, Gadhiya S, Jagtap SS. Gestational trophoblastic disease- clinicopathological study at tertiary care hospital. J Clin Diagn Res. 2017;11(8):EC27. DOI: https://doi.org/10.7860/JCDR/2017/27232.10458
Lakra P, Sangwan V, Siwach S, Kansal R, Mahendru R, Sharma A. Outcome of gestational trophoblastic disease in a rural tertiary centre of Haryana, India. Int J Reprod Contracept Obstet Gynecol. 2016;6(1):271. DOI: https://doi.org/10.18203/2320-1770.ijrcog20164673
Ifunanya NJ, Okwuchukwu OV, Chukwu IC, Nobert OC, Blessing O, Chibuzor UD, et al. Gestational trophoblastic diseases: a review of the clinical presentation and management at the Alex Ekwueme Federal University Teaching Hospital Abakaliki. Case Rep Clin Med. 2019;8(06):164. DOI: https://doi.org/10.4236/crcm.2019.86020
Anuma ON, Umeora OU, Obuna JA, Agwu UM. Profiling gestational trophoblastic disease in a tertiary Hospital in South-East Nigeria. Trop J Obstet Gynaecol. 2009;26(2):157-64.
Thakuria SK, Deka MK, Sheikh SA. A clinicopathological study of gestational trophoblastic disease in a tertiary care centre of southern Assam. Int J Res Med Sci. 2021;9(4):1169. DOI: https://doi.org/10.18203/2320-6012.ijrms20211370
Malovrh EP, Lukinovič N, Sobočan M, Knez J. Outcomes of gestational trophoblastic disease management: a single centre review. Medicina. 2023;59(9):1632. DOI: https://doi.org/10.3390/medicina59091632
Feltmate CM, Batorfi J, Fulop V, Goldstein DP, Doszpod J, Berkowitz RS. Human chorionic gonadotropin follow-up in patients with molar pregnancy: a time for reevaluation. Obstet Gynecol. 2003;101(4):732-6. DOI: https://doi.org/10.1097/00006250-200304000-00020
Massad LS, Abu-Rustum NR, Lee SS, Renta V. Poor compliance with postmolar surveillance and treatment protocols by indigent women. Obstet Gynecol. 2000;96(6):940-4. DOI: https://doi.org/10.1097/00006250-200012000-00014
Downloads
Published
How to Cite
Issue
Section
